Digital Look

Welcome to Digital Look++,
you are not logged in

HUTCHMED (China) Limited (HCM)

Pharma and Biotech

0.000p

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-20	227.98	(189.73)	(18.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-21	356.13	(215.74)	(0.25)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	426.41	(410.42)	(43.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	838.00	58.31	12.00¢	30.9	n/a	n/a	n/a	0.0%
31-Dec-24	630.20	(1.11)	4.00¢	76.9	n/a	-67%	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Vesting of awards under Long Term Incentive Plan	21-Oct-2025	09:30	RNS
Appointment of Independent Non-executive Director	14-Oct-2025	09:30	RNS
Total Voting Rights	30-Sep-2025	09:30	RNS

Hutchmed enrols last patient in phase three lung...	05-Nov-2025	ShareCast
Hutchmed takes wraps off expanding oncology pipe...	03-Nov-2025	ShareCast
Hutchmed upbeat on preclinical data for novel ca...	23-Oct-2025	ShareCast

Chinese medicine firm employs Cambridge Universi...	23-Dec-2009	Guardian
Joint venture offers food for growth	09-Oct-2009	The Scotsman
Chi-Med unveils maiden profit	31-Jul-2009	The Scotsman

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.